Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

BACKGROUND: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF recep...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A
Format: Artigo
Idioma:Inglês
Publicat: Lancet Pub. Group 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648082/
https://ncbi.nlm.nih.gov/pubmed/26179201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00139-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars